Navigation Links
YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES
Date:12/10/2009

ErbB-2, ERBB2), is associated with more aggressive breast cancers. Unwanted targeting of HER2 on cardiac myocytes (heart tissue) has been associated with damage to the heart in up to 28% of patients currently treated with trastuzumab when combined with certain chemotherapies (www.herceptin.com Full Prescribing Information).

Dr. Gregory P. Adams, Co-Leader, Molecular Medicine Program, Department of Medical Oncology, Fox Chase Cancer Center commented, "Antibodies with better selectivity for tumor tissue over normal tissues are an important goal for improved cancer therapy. They may offer improved efficacy over less selective antibodies on their own and their major advantage should lie in the precise delivery of toxic payloads to tumor cells, sparing toxicity to normal tissues."

The collaborative program is a multi-target, parallel-discovery research project funded by YM and NRC-BRI to develop YM's IntelliMab(TM) technology, a proprietary platform for generating new therapeutic antibodies that are designed to be as effective as, but safer than the current generation of antibodies. Collateral toxicity is an important challenge for numerous antibodies that indiscriminately target receptor in normal tissues as well as in the intended cancer cells. Furthermore, these antibodies are expected to be ideal candidates for delivering potent toxins to cancer cells. Depending on the cancer target selected, IntelliMab(TM) antibodies will be developed as naked antibodies and/or antibody conjugates. The YM team is led by Mr. Sean Thompson, Vice President of Strategic Projects and Corporate Development, who is collaborating with Dr. Maureen O'Connor, Leader of the NRC Genomics and Health Initiative Cancer Program.

"YM BioSciences has combined forces with the NRC-BRI, harnessing its world-class facility and considerable scientific expertise to create what we expect will be a suite of novel, high-val
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Cell Biosciences Acquires Protein Forest
2. Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc.
3. Dow AgroSciences, Agrisoma Biosciences Announce Research and Commercial License Option Agreement for Agricultural Crops
4. Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference
5. YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA
6. American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor
7. Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS
8. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING
9. Regado Biosciences to Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17, 2009
10. YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS
11. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 16, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 23, 2013 The maker community is ... of inventions. They focus on learning practical skills while ... gravitate toward bringing their ideas to life via crowdfunding. ... works on making projects using biology. Glowing Plant has ... to make them glow with bioluminescence genes, and has ...
(Date:5/23/2013)... MARINO, Calif. , May 23, 2013 /PRNewswire/ ... today a strategic alliance with DAK Renewable Research ... the corn oil yield. VG Energy is a ... (OTC Pink: VGLS). VG Energy,s exclusively ... to increase the oil yield in plants, possessing ...
(Date:5/23/2013)... 2013 Virobay, Inc. today announced that their ... an important milestone, as Virobay has now initiated a ... cathepsin S inhibitor.   The first Phase ... study designed to evaluate the safety, tolerability, pharmacokinetics and ... "The initiation of this Phase 1 trial ...
(Date:5/23/2013)... On April 19th the Center for Disease ... the growing antibiotic resistant bacteria that may be lurking ... study were released late last month showing higher antibiotic ... years. For those suffering from bacteria driven acne, Probiotic ... in food, may eventually help breed acne causing bacteria. ...
Breaking Biology Technology:Glowing Plant Releases Maker Kit, Enabling Anyone to Make a Glowing Plant at Home 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 3Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3Acne Cream, Probiotic Action Shares News on How Some Food may Breed Acne Causing Bacteria 2
... Warrant Amount by an Additional ... $44.5 million, ... that a single institutional investor,has agreed to purchase, for $44.5 million, newly ... per share, and a,warrant to purchase approximately 28.2 million shares of common ...
... eResearchTechnology,Inc. (eRT or the Company), (Nasdaq: ERES ... technology, ePRO and other services to the,pharmaceutical, biotechnology, ... of Mr. Keith D. Schneck as Executive Vice,President ... Mr. Schneck joins eRT with over 30 ...
... Plans for Regaining Compliance - - NASDAQ Hearing Panel ... ... Other NASDAQ Capital Market Initial Listing ... TUSTIN, Calif., July 23 Peregrine,Pharmaceuticals, Inc. (Nasdaq: PPHM ...
Cached Biology Technology:Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase $44.5 Million of Units Consisting of Senior Convertible Notes and Warrants 2Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase $44.5 Million of Units Consisting of Senior Convertible Notes and Warrants 3eResearchTechnology Names New Chief Financial Officer 2eResearchTechnology Names New Chief Financial Officer 3Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule 2Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule 3Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule 4
(Date:5/23/2013)... MADISON, Wis. In an age when microbial pathogens ... to tamp down infection, a team of Wisconsin scientists ... of curbing the bacteria that cause staph infections. , ... Chemical Society , a group led by University of ... interfere with the "quorum sensing" behavior of Staphylococcus ...
(Date:5/22/2013)... Screening Trial (NLST) investigators also conclude that the ... low-dose computed tomography (LDCT) versus chest X-ray (CXR) ... is achievable at experienced screening centers in the ... to share with their patients about the benefits ... today,s publication in the New England Journal ...
(Date:5/22/2013)... developed a novel technique that can detect molecular variants ... is one of the most important, though time-consuming, processes ... paper in Nature , post-doctoral researcher David Patterson, ... of the Center for Free-Electron Laser Science (CFEL) in ... microwave fields to identify molecular variants apart, and to ...
Breaking Biology News(10 mins):University of Wisconsin chemists find new compounds to curb staph infection 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 3Detecting mirror molecules 2Detecting mirror molecules 3
... D.C. A class of Alzheimer,s disease drugs currently ... by traumatic brain injury in animals, researchers at Georgetown ... publication of Nature Medicine . They say ... potentially do something no other drug has been able ...
... 15, 2009 Researchers at Memorial Sloan-Kettering Cancer Center ... tendency to develop some blood disorders may be inherited. ... , identifies a common genetic sequence abnormality that enhances ... linked to certain blood diseases. The investigators carried ...
... National Institute of Environmental Health Sciences (NIEHS), part of ... major presence at the annual Society of Toxicology (SOT) ... the National Toxicology Program (NTP), which NIEHS administers, as ... newest advances, applications and thinking in the field of ...
Cached Biology News:Alzheimer's disease therapeutic prevents long-term damage from TBI in pre-clinical studies 2Alzheimer's disease therapeutic prevents long-term damage from TBI in pre-clinical studies 3Hear about emerging trends in toxicology research 2
LIVE/DEAD® Sperm Viability Kit *200-1000 assays*...
Human Xg Affinity Purified Polyclonal Ab Keywords: Xg glycoprotein, hereditary hemorrhagic telangiectasia Protein Family: ...
Vitellogenin (Japanese medaka) Standard...
Mouse Collagen IV...
Biology Products: